Outcomes Research in Rheumatic Diseases

风湿性疾病的结果研究

• 批准号: 9526645
• 负责人: DINESH KHANNA
• 金额: $ 13.28万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9526645
• 关键词: Address; Advocate; Antibody-drug conjugates; Area; Autoimmunity; Award; Blood; Charge; Clinical; Clinical Research; Clinical Trials Design; Computerized Medical Record; Consensus; Cutaneous; Data; Development; Diffuse; Discipline; Documentation; Dose; Double-Blind Method; Ensure; Exercise; Faculty; Fostering; Foxes; Funding; Future; Goals; Grant; Growth; Health Personnel; Immune Tolerance; Information Resources Management; Information Systems; Institution; International; Internet; Interstitial Lung Diseases; Journals; Leadership; Link; Measurement; Measures; Medical Students; Medicine; Mentors; Michigan; Molecular Profiling; National Institute of Allergy and Infectious Disease; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Outcome Measure; Outcomes Research; Patient Outcomes Assessments; Patient-Focused Outcomes; Patients; Peer Review; Phase; Pilot Projects; Placebos; Postdoctoral Fellow; Protocols documentation; Publishing; Randomized Controlled Trials; Reporting; Research; Research Personnel; Research Project Grants; Research Support; Research Training; Rheumatism; Role; Safety; Scleroderma; Secure; Self Efficacy; Self Management; Skin; Systemic Scleroderma; T-Lymphocyte; TNFRSF8 gene; Techniques; Time; Training; Training Programs; United States National Institutes of Health; Universities; base; career; clinical practice; comparative effectiveness; improved; indexing; interest; next generation; patient oriented research; patient-clinician communication; point of care; primary outcome; professor; programs; prospective; recruit; response; safety study; self-management program; skills; subcutaneous; undergraduate student

Project Summary/Abstract Outcomes research in rheumatic diseases Dr. Dinesh Khanna is a professor of medicine at the University of Michigan (UM) and director of the UM Scleroderma Program. He seeks the extension of the K24 Mid-Career Investigator Award in Patient-Oriented Research (POR) to continue this successful research program while dedicating significant time for mentoring the next generation of undergraduates, medical students, residents, clinical and post-doctoral fellows, and junior faculty trainees. The goals of the K24 renewal application are to support the candidate's continued impact as a mentor and assume leadership roles in collaborative POR programs, to continue the growth of a research training program for POR at the UM, and to recruit new mentees who are interested in POR. Since the successful funding of the initial K24 grant, the candidate has actively mentored trainees and junior faculty on different POR projects who have published in peer-reviewed journals and received independent funding. The candidate has launched successful collaborative links with other disciplines and institutions in the pursuit of program excellence, and there is strong institutional support to create this program. The K24 grant would preserve 30% of the candidate's effort and relieve future clinical and administrative responsibilities. A diverse portfolio of currently funded research opportunities exists for future trainees in POR. The research proposed includes four current projects and one new project addressing POR areas of patient reported outcomes, outcome measures, and clinical trial design. The currently funded studies include: 1) Taking charge of systemic sclerosis: Improving patient outcomes through self-management (funded by PCORI); 2) Development of a systemic sclerosis-associated interstitial lung disease combined response index (R01, funded by NIH/NIAMS); 3) An investigator-initiated, multicenter international phase II pilot study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis—a double-blind, placebo-controlled, randomized controlled trial (funded by NIH/NIAID, University of Michigan Autoimmunity Center of Excellence and Bristol Myers Squibb); and 4) A dose escalation safety study of brentuximab vedotin in diffuse dutaneous Systemic Sclerosis (funded by NIH/NIAID/Immune Tolerance Network). The aim of the new proposed study is to implementation the NIH Patient-Reported Outcomes Measurement Information System (PROMIS®) in clinical practice using a pilot cluster randomized controlled trial.

项目摘要/摘要 风湿性疾病的结果研究 Dinesh Khanna博士是密歇根大学（UM）的医学教授和UM的主任 硬皮病计划。他寻求延长K24中级研究员奖，以患者为导向 研究（POR）继续这项成功的研究计划，同时花费大量时间进行心理精神 下一代的本科生，医学生，居民，临床和博士后研究员以及 初级教师。 K24更新申请的目标是支持候选人的继续 作为心理的影响，并在协作计划中扮演领导角色，以继续增长 在UM的POR研究培训计划，并招募对POR感兴趣的新受训者。 自从最初的K24赠款的成功基础以来，候选人积极修改培训和初级 在同行评审期刊上发表并获得独立的不同POR项目的教师 资金。候选人已与其他学科和机构成功启动了合作链接 追求卓越计划，并且有强大的机构支持来创建该计划。 K24赠款 将保留30％的候选人努力，并挽救未来的临床和行政责任。一个 目前资助的研究机会的各种投资组合存在于POR的未来学员。 拟议的研究包括四个当前的项目和一个针对患者的POR领域的新项目 报告的结果，结果指标和临床试验设计。当前资助的研究包括：1） 负责系统性硬化症：通过自我管理改善患者的结果（由 pcori）; 2）发展系统性硬化症相关的间质肺疾病联合反应指数 （R01，由NIH/NIAMS资助）； 3）调查员发动的，多中心国际II期试点研究 评估皮下ABATACEPT与安慰剂在弥漫性皮肤硬化症中 - 双盲 安慰剂对照，随机对照试验（由密歇根大学自动免疫的NIH/NIAID资助 卓越中心和Bristol Myers Squibb）； 4）Brentuximab vedotin的剂量升级安全研究 在弥漫性荷兰系统性硬化症中（由NIH/NIAID/免疫耐受性网络资助）。目的 新提出的研究是实施NIH患者报告的结果测量信息 系统（Promis®）在临床实践中使用飞行员群集随机对照试验。